Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Gold/Mining/Energy : Big Dog's Boom Boom Room -- Ignore unavailable to you. Want to Upgrade?

To: energyplay who wrote (51408)	10/13/2005 6:37:09 PM
From: Elroy Jetson	Read Replies (2) \| Respond to of 206182

The problem with Peramivir is that you can't get your hands on it, leaving us with Relenza, Tamiflu and Amantadine for now. Slight genetic changes in the virus can make its replication more or less susceptible to being blocked by these drugs. Peramivir trials were discontinued because the drug was ineffective against the common flu. Recently, some viral cultures have shown it to be effective against H5N1 bird flu, so development will begin again, but you can't get your hands on it until it is approved by the FDA. There is no evidence that Peramivir is more or less effective against H5N1 than existing drugs but, when dealing with a quickly changing virus, more drugs to choose from is better. I'm also a big fan of interferon-alpha for viral infections as it both: directs the immune system to turn-off and kill virally infected cells; and also down-regulates an excessive general immune response which can be counter-productive in fighting a virus. Interferon-alpha 10 mu is sold as either Roferon or Intron-A. The H5N1 bird flu has already demonstrated human to human transmission. But it requires a few more genetic changes to be able to achieve more prolific human to human transmission. .